CI Cigna

XNYS Up Alert

Health Care

· How we analyze

About the company

Cigna is a US healthcare company. Through its Evernorth division with Express Scripts it manages pharmacy benefits and runs mail-order and specialty pharmacies. It also provides health insurance for employers in the US and international health plans. As of Oct 11, 2026

Fact sheet (from the annual report) Health insurance and health plans · Bloomfield, USA

According to the company, The Cigna Group is a global health company with health insurance and pharmacy services. The Evernorth Health Services area comprises the segments for pharmacy benefit services and for specialty and care services. These include pharmacy claims processing, management of pharmacy networks and the specialty pharmacy Accredo. Customers of this area include health insurers, employers, union plans and government health programs, among others. The Cigna Healthcare segment offers health insurance for employers, individuals and globally mobile customers. The group divested its Medicare Advantage business in 2025.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.4%
  • 7 days +2.4%
  • 30 days +12.4%
  • 1 year +1.3%
Day range (last trading day)
−0.4%Price at 21% of the range+1.7%
52-week range
−21.7%Price at 86% of the range+3.4%
Distance from the all-time high
−17.5%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin and debt compared with the sector – in detail in the fundamental analysis further down. The chart shows the candles without a buy zone.

Growth: greenMargin: yellowDebt: gray

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:CI

Fundamental analysis

Cigna · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 26, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 2 without data 1 of 6 criteria met Growth Revenue and earnings per share · 1 without data 4 of 6 criteria met Dividend Level, consistency, coverage · 2 without data 5 of 5 criteria met Financial strength Piotroski, debt, liquidity · 1 without data 4 of 5 criteria met

Quality 1 of 6 met · 2 without data

  • not met: Gross margin above 40% 21.8%
  • not met: Operating margin above 15% 3.3%
  • not met: Net margin above 10% 2.2%
  • not met: Return on equity above 15% 14.3%
  • no data: Free cash flow margin above 10% not stated in the SEC filings
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • no data: Free cash flow positive in each of the last 3 fiscal years not stated in the SEC filings
  • not met: Equity ratio above 30% 26.4%
Gross margin

21.8% Fiscal year 2025

Rank 13 of 100: higher than 13% of 153 peers (All). weak.

Rank 8 of 100: higher than 8% of 20 peers (Sector). weak.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Operating margin

3.3% Fiscal year 2025

Rank 25 of 100: higher than 25% of 192 peers (All). weak.

Rank 28 of 100: higher than 28% of 20 peers (Sector). weak.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

2.2% Fiscal year 2025

Rank 19 of 100: higher than 19% of 237 peers (All). weak.

Rank 21 of 100: higher than 21% of 26 peers (Sector). weak.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

14.3% Fiscal year 2025

Rank 44 of 100: higher than 44% of 218 peers (All). medium.

Rank 50 of 100: higher than 50% of 21 peers (Sector). medium.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

3.8% Fiscal year 2025 (total assets at year end)

Rank 33 of 100: higher than 33% of 238 peers (All). medium.

Rank 25 of 100: higher than 25% of 26 peers (Sector). weak.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

26.4% Fiscal year 2025

Rank 38 of 100: higher than 38% of 239 peers (All). medium.

Rank 33 of 100: higher than 33% of 26 peers (Sector). medium.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Growth 4 of 6 met · 1 without data

  • met: Over 3 years, revenue grew by more than 5% per year +15.0%
  • met: Over 5 years, revenue grew by more than 5% per year +11.4%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • not met: Over 3 years, EPS grew by more than 5% per year +1.4%
  • not met: Over 5 years, EPS grew by more than 5% per year −0.7%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +11.2%
Revenue growth 3 years

+15.0% per year

Rank 70 of 100: higher than 70% of 230 peers (All). strong.

Rank 86 of 100: higher than 86% of 25 peers (Sector). strong.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+11.4% per year

Rank 52 of 100: higher than 52% of 217 peers (All). medium.

Rank 66 of 100: higher than 66% of 25 peers (Sector). medium.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

EPS growth 3 years

+1.4% per year

Rank 26 of 100: higher than 26% of 157 peers (All). weak.

Rank 39 of 100: higher than 39% of 22 peers (Sector). medium.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−0.7% per year

Rank 13 of 100: higher than 13% of 146 peers (All). weak.

Rank 23 of 100: higher than 23% of 20 peers (Sector). weak.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 5 of 5 met · 2 without data

  • met: Pays a dividend 6.04 USD
  • met: Payout ratio at most 60% of earnings 27%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +172.8%
  • no data: Free cash flow per share covers the dividend not stated in the SEC filings
  • no data: Dividends paid over the last 5 years covered by free cash flow dividends paid or free cash flow reported for fewer than 3 years
Payout ratio

27% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+172.8% per year

Rank 100 of 100: higher than 100% of 118 peers (All). strong.

Rank 97 of 100: higher than 97% of 16 peers (Sector). strong.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Financial strength 4 of 5 met · 1 without data

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.74
  • not met: Current assets cover current liabilities 0.85
  • met: Positive equity 41.7B USD
  • met: In 5 years, share count up by at most 5% −27.1%
  • no data: Free cash flow positive in the last fiscal year capital expenditure or operating cash flow not reported
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 72 of 100: higher than 72% of 134 peers (All). strong.

Rank 63 of 100: higher than 63% of 19 peers (Sector). medium.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.74 at fiscal year end

Rank 41 of 100: lower than 41% of 199 peers (All). medium.

Rank 36 of 100: lower than 36% of 18 peers (Sector). medium.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.85 at fiscal year end

Rank 12 of 100: higher than 12% of 215 peers (All). weak.

Rank 13 of 100: higher than 13% of 26 peers (Sector). weak.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−27.1% in 5 years

Rank 98 of 100: lower than 98% of 199 peers (All). strong.

Rank 94 of 100: lower than 94% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+11.4% per year), at least as fast as the sector median.
  • Light red: Net income (total) shrank over 5 years (−6.8% per year); per share −0.7% per year.
  • Light yellow: Net margin 2.2%, below the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 39.8B USD · Net income 1.8B USD · Net margin 4.6%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 41.8B USD · Net income 2.2B USD · Net margin 5.3%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 48.7B USD · Net income 2.6B USD · Net margin 5.4%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 153.6B USD · Net income 5.1B USD · Net margin 3.3%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 160.4B USD · Net income 8.5B USD · Net margin 5.3%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 174.1B USD · Net income 5.4B USD · Net margin 3.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 180.5B USD · Net income 6.7B USD · Net margin 3.7%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 195.3B USD · Net income 5.2B USD · Net margin 2.6%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 247.1B USD · Net income 3.4B USD · Net margin 1.4%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 274.9B USD · Net income 6.0B USD · Net margin 2.2%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 274.9B USD · Net income 6.0B USD · Net margin 2.2%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 21.8 USD gross profit, 3.3 USD operating income and 2.2 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue274.9B USD100.0%
Gross profit59.9B USD21.8%
Cost of revenue215.0B USD78.2%
Operating income9.2B USD3.3%
Operating expenses50.7B USD18.4%
Net income6.0B USD2.2%
Interest expense1.4B USD0.5%
Taxes1.5B USD0.5%
Other350.0M USD0.1%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 5.1% to 3.3%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin not available · Operating margin 7.8% · Net margin 4.7%
  2. Fiscal year 2017: Gross margin not available · Operating margin 9.4% · Net margin 5.4%
  3. Fiscal year 2018: Gross margin not available · Operating margin 8.6% · Net margin 5.4%
  4. Fiscal year 2019: Gross margin 36.4% · Operating margin 5.3% · Net margin 3.3%
  5. Fiscal year 2020: Gross margin 35.5% · Operating margin 5.1% · Net margin 5.3%
  6. Fiscal year 2021: Gross margin 32.5% · Operating margin 4.6% · Net margin 3.1%
  7. Fiscal year 2022: Gross margin 30.8% · Operating margin 4.7% · Net margin 3.7%
  8. Fiscal year 2023: Gross margin 31.5% · Operating margin 4.4% · Net margin 2.6%
  9. Fiscal year 2024: Gross margin 26.1% · Operating margin 3.8% · Net margin 1.4%
  10. Fiscal year 2025: Gross margin 21.8% · Operating margin 3.3% · Net margin 2.2%

Returns

Return on equity fell in 5 years from 16.8% to 14.3%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 13.6% · Return on assets not available
  2. Fiscal year 2017: Return on equity 16.3% · Return on assets 3.6%
  3. Fiscal year 2018: Return on equity 6.4% · Return on assets 1.7%
  4. Fiscal year 2019: Return on equity 11.3% · Return on assets 3.3%
  5. Fiscal year 2020: Return on equity 16.8% · Return on assets 5.4%
  6. Fiscal year 2021: Return on equity 11.4% · Return on assets 3.5%
  7. Fiscal year 2022: Return on equity 14.9% · Return on assets 4.6%
  8. Fiscal year 2023: Return on equity 11.2% · Return on assets 3.4%
  9. Fiscal year 2024: Return on equity 8.4% · Return on assets 2.2%
  10. Fiscal year 2025: Return on equity 14.3% · Return on assets 3.8%

Equity and long-term debt

The equity ratio fell in 5 years from 32.4% to 26.4%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 13.7B USD · Long-term debt not available
  2. Fiscal year 2017: Equity 13.7B USD · Long-term debt 5.2B USD
  3. Fiscal year 2018: Equity 41.0B USD · Long-term debt 39.5B USD
  4. Fiscal year 2019: Equity 45.3B USD · Long-term debt 31.9B USD
  5. Fiscal year 2020: Equity 50.3B USD · Long-term debt 29.5B USD
  6. Fiscal year 2021: Equity 47.1B USD · Long-term debt 31.1B USD
  7. Fiscal year 2022: Equity 44.9B USD · Long-term debt 28.1B USD
  8. Fiscal year 2023: Equity 46.2B USD · Long-term debt 28.2B USD
  9. Fiscal year 2024: Equity 41.0B USD · Long-term debt 28.9B USD
  10. Fiscal year 2025: Equity 41.7B USD · Long-term debt 30.9B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 0.77 to 0.85.

Current ratio
  1. Fiscal year 2016: Current ratio not available
  2. Fiscal year 2017: Current ratio 0.85
  3. Fiscal year 2018: Current ratio 0.64
  4. Fiscal year 2019: Current ratio 0.74
  5. Fiscal year 2020: Current ratio 0.77
  6. Fiscal year 2021: Current ratio 0.83
  7. Fiscal year 2022: Current ratio 0.73
  8. Fiscal year 2023: Current ratio 0.77
  9. Fiscal year 2024: Current ratio 0.84
  10. Fiscal year 2025: Current ratio 0.85

Cash flow

Free cash flow rose in 3 years from 3.6B USD to 8.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 4.0B USD · Capital expenditure 461.0M USD · Free cash flow 3.6B USD
  2. Fiscal year 2017: Operating cash flow 4.1B USD · Capital expenditure 471.0M USD · Free cash flow 3.6B USD
  3. Fiscal year 2018: Operating cash flow 3.8B USD · Capital expenditure 528.0M USD · Free cash flow 3.2B USD
  4. Fiscal year 2019: Operating cash flow 9.5B USD · Capital expenditure 1.1B USD · Free cash flow 8.4B USD
  5. Fiscal year 2020: Operating cash flow 10.4B USD · Capital expenditure not available · Free cash flow not available
  6. Fiscal year 2021: Operating cash flow 7.2B USD · Capital expenditure not available · Free cash flow not available
  7. Fiscal year 2022: Operating cash flow 8.7B USD · Capital expenditure not available · Free cash flow not available
  8. Fiscal year 2023: Operating cash flow 11.8B USD · Capital expenditure not available · Free cash flow not available
  9. Fiscal year 2024: Operating cash flow 10.4B USD · Capital expenditure not available · Free cash flow not available
  10. Fiscal year 2025: Operating cash flow 9.6B USD · Capital expenditure not available · Free cash flow not available

Share count

The share count fell in 5 years by 27.1% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 259.6M
  2. Fiscal year 2017: Diluted share count 255.1M
  3. Fiscal year 2018: Diluted share count 250.2M
  4. Fiscal year 2019: Diluted share count 379.8M
  5. Fiscal year 2020: Diluted share count 368.4M
  6. Fiscal year 2021: Diluted share count 341.0M
  7. Fiscal year 2022: Diluted share count 313.1M
  8. Fiscal year 2023: Diluted share count 296.9M
  9. Fiscal year 2024: Diluted share count 283.2M
  10. Fiscal year 2025: Diluted share count 268.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
6.04 USD · Fiscal year 2025
Dividend growth per year
3 y +10.5%5 y –10 y –
Years without a cut
at least 8 as far as the data goes
Payout ratio
of earnings 27% of free cash flow –
To shareholders (5 years)
35.6B USD 79% through repurchases
Share count over 5 years
−27.1% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 0.04 USD to 6.04 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share not available
  2. Fiscal year 2017: Dividend per share 0.04 USD
  3. Fiscal year 2018: Dividend per share 0.04 USD
  4. Fiscal year 2019: Dividend per share 0.04 USD
  5. Fiscal year 2020: Dividend per share 0.04 USD
  6. Fiscal year 2021: Dividend per share 4.00 USD
  7. Fiscal year 2022: Dividend per share 4.48 USD
  8. Fiscal year 2023: Dividend per share 4.92 USD
  9. Fiscal year 2024: Dividend per share 5.60 USD
  10. Fiscal year 2025: Dividend per share 6.04 USD

Payout ratios

The payout ratio rose in 5 years from 0.2% to 27.2%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) not available · Payout ratio (free cash flow) 0.3%
  2. Fiscal year 2017: Payout ratio (earnings) 0.5% · Payout ratio (free cash flow) 0.3%
  3. Fiscal year 2018: Payout ratio (earnings) 0.4% · Payout ratio (free cash flow) 0.3%
  4. Fiscal year 2019: Payout ratio (earnings) 0.3% · Payout ratio (free cash flow) 0.2%
  5. Fiscal year 2020: Payout ratio (earnings) 0.2% · Payout ratio (free cash flow) not available
  6. Fiscal year 2021: Payout ratio (earnings) 25.4% · Payout ratio (free cash flow) not available
  7. Fiscal year 2022: Payout ratio (earnings) 21.0% · Payout ratio (free cash flow) not available
  8. Fiscal year 2023: Payout ratio (earnings) 28.3% · Payout ratio (free cash flow) not available
  9. Fiscal year 2024: Payout ratio (earnings) 46.2% · Payout ratio (free cash flow) not available
  10. Fiscal year 2025: Payout ratio (earnings) 27.2% · Payout ratio (free cash flow) not available

What goes back to shareholders

Over 5 years, 35.6B USD went back to shareholders, 79% of it through share repurchases. This was offset by new shares issued for 1.4B USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD Dividends partly reported as declared rather than paid.
  1. Fiscal year 2016: Dividends paid 10.0M USD · Share repurchases 139.0M USD · New shares issued (including employee plans) 36.0M USD · Free cash flow 3.6B USD
  2. Fiscal year 2017: Dividends paid 10.0M USD · Share repurchases 2.7B USD · New shares issued (including employee plans) 131.0M USD · Free cash flow 3.6B USD
  3. Fiscal year 2018: Dividends paid 10.0M USD · Share repurchases 342.0M USD · New shares issued (including employee plans) 68.0M USD · Free cash flow 3.2B USD
  4. Fiscal year 2019: Dividends paid 15.0M USD · Share repurchases 2.0B USD · New shares issued (including employee plans) 224.0M USD · Free cash flow 8.4B USD
  5. Fiscal year 2020: Dividends paid 15.0M USD · Share repurchases 4.0B USD · New shares issued (including employee plans) 376.0M USD · Free cash flow not available
  6. Fiscal year 2021: Dividends paid 1.3B USD · Share repurchases 7.7B USD · New shares issued (including employee plans) 326.0M USD · Free cash flow not available
  7. Fiscal year 2022: Dividends paid 1.4B USD · Share repurchases 7.6B USD · New shares issued (including employee plans) 389.0M USD · Free cash flow not available
  8. Fiscal year 2023: Dividends paid 1.5B USD · Share repurchases 2.3B USD · New shares issued (including employee plans) 187.0M USD · Free cash flow not available
  9. Fiscal year 2024: Dividends paid 1.6B USD · Share repurchases 7.0B USD · New shares issued (including employee plans) 305.0M USD · Free cash flow not available
  10. Fiscal year 2025: Dividends paid 1.6B USD · Share repurchases 3.6B USD · New shares issued (including employee plans) 203.0M USD · Free cash flow not available

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Cigna next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison CI, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health 402.1B USD +8.4%45.0%1.2%0.4%2.4%29.7%1.9%7/9
CI Cigna this stock 274.9B USD +11.4%21.8%3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+11.4% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 11.4% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−6.8% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: −0.7% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 6.8% per year on average. The median company in the sector reached +7.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

2.2% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 2.17 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 5.3%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.68 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.68 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

27% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.27 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
274.9B USD
Revenue vs. prior year
+11.2%
Net income (FY)
6.0B USD
Net income vs. prior year
+73.5%
EPS (FY)
22.18 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+219.2%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Jun 30, 2026 (filed Jul 30, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 274.9B6.0B 2.2% 22.18 6.04 27%
2024Dec 31, 2024 247.1B3.4B 1.4% 12.12 5.60 46%
2023Dec 31, 2023 195.3B5.2B 2.6% 17.39 4.92 28%
2022Dec 31, 2022 180.5B6.7B 3.7% 21.30 4.48 21%
2021Dec 31, 2021 174.1B5.4B 3.1% 15.73 4.00 25%
2020Dec 31, 2020 160.4B8.5B 5.3% 22.96 0.04 0%
2019Dec 31, 2019 153.6B5.1B 3.3% 13.44 0.04 0%
2018Dec 31, 2018 48.7B2.6B 5.4% 10.54 0.04 0%
2017Dec 31, 2017 41.8B2.2B 5.3% 8.77 0.04 0%
2016Dec 31, 2016 39.8B1.8B 4.6% 7.19 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 71.7B1.7B 2.3% 6.29 1.56 25%
Q1/26Mar 31, 2026 68.5B1.7B 2.4% 6.26 1.56 25%
Q4/25*Dec 31, 2025 72.5B– – – 1.51 –
Q3/25Sep 30, 2025 69.7B2.0B 2.8% 6.98 1.51 22%
Q2/25Jun 30, 2025 67.2B1.5B 2.3% 5.71 1.51 26%
Q1/25Mar 31, 2025 65.5B1.3B 2.0% 4.85 1.51 31%
Q4/24*Dec 31, 2024 65.6B– – – 1.40 –
Q3/24Sep 30, 2024 63.7B825.0M 1.3% 2.63 1.40 53%
Q2/24Jun 30, 2024 60.5B1.6B 2.7% 5.45 1.40 26%
Q1/24Mar 31, 2024 57.3B−212.0M −0.4% −0.97 1.40 –
Q4/23*Dec 31, 2023 51.1B– – – 1.23 –
Q3/23Sep 30, 2023 49.0B1.4B 3.0% 4.74 1.23 26%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $6.3M2 people −$6.3M
6 months $00 people $65.7M4 people −$65.7M
12 months $999.9K1 person $66.8M4 people −$65.8M

Latest transactions

  • Sep 3, 2026 Neville Everett Officer Open-market sale · 10b5-1 plan 617 shares · $175.3K · SEC
  • Aug 18, 2026 Jones Nicole S Officer Open-market sale · 10b5-1 plan 2,677 shares · $748.5K · SEC
  • Aug 4, 2026 Jones Nicole S Officer Open-market sale · 10b5-1 plan 19,436 shares · $5.4M · SEC
  • Jun 12, 2026 Kates Jamie G Officer Open-market sale 899 shares · $268.5K · SEC
  • May 12, 2026 Cordani David Chief executive (CEO), Director Open-market sale · 10b5-1 plan 2,231 shares · $666.0K · SEC
  • May 12, 2026 Cordani David Chief executive (CEO), Director Open-market sale · 10b5-1 plan 15,319 shares · $4.6M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +70

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows-10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)26.5
Rel. strength 60 d+7.0%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on CI yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: CI

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close